JNJ

192.08

-0.38%↓

ABT

126.36

-1.14%↓

MDT

94.19

-1.71%↓

VEEV

291.41

+0.69%↑

A

147.65

+1.19%↑

JNJ

192.08

-0.38%↓

ABT

126.36

-1.14%↓

MDT

94.19

-1.71%↓

VEEV

291.41

+0.69%↑

A

147.65

+1.19%↑

JNJ

192.08

-0.38%↓

ABT

126.36

-1.14%↓

MDT

94.19

-1.71%↓

VEEV

291.41

+0.69%↑

A

147.65

+1.19%↑

JNJ

192.08

-0.38%↓

ABT

126.36

-1.14%↓

MDT

94.19

-1.71%↓

VEEV

291.41

+0.69%↑

A

147.65

+1.19%↑

JNJ

192.08

-0.38%↓

ABT

126.36

-1.14%↓

MDT

94.19

-1.71%↓

VEEV

291.41

+0.69%↑

A

147.65

+1.19%↑

Search

Omeros Corp

Cerrado

SectorSanidad

7.65 -0.78

Resumen

Variación precio

24h

Actual

Mínimo

7.59

Máximo

7.91

Métricas clave

By Trading Economics

Ingresos

8M

-25M

Margen de beneficios

-8,121.359

Empleados

202

EBITDA

9.3M

-26M

Recomendaciones

By TipRanks

Recomendaciones

Comprar

Estimación a 12 Meses

+71.63% upside

Dividendos

By Dow Jones

Próximas Ganancias

12 nov 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

284M

561M

Apertura anterior

8.43

Cierre anterior

7.65

Noticias sobre sentimiento de mercado

By Acuity

18%

82%

29 / 371 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Very Strong Bearish Evidence

Omeros Corp Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

15 oct 2025, 15:36 UTC

Adquisiciones, fusiones, absorciones

Novo Nordisk to Buy Blood Disease Drug From Omeros for Up to $2.1 Billion -- Update

15 oct 2025, 13:27 UTC

Adquisiciones, fusiones, absorciones

Novo Nordisk to Pay Omeros Up to $2.1 Billion for Blood Disease Drug

15 oct 2025, 12:33 UTC

Adquisiciones, fusiones, absorciones

Novo Nordisk: Omeros Could Recieve Up to Total of $2.1B Including Potential Milestones, Tiered Royalties

15 oct 2025, 12:32 UTC

Adquisiciones, fusiones, absorciones

Novo Nordisk: Omeros Eligible to Receive $340M in Upfront and Near-Term Milestone Payments

15 oct 2025, 12:32 UTC

Adquisiciones, fusiones, absorciones

Novo Nordisk Will Be Granted Exclusive Global Rights to Develop, Commercialise Zaltenibart in All Indications

15 oct 2025, 12:32 UTC

Adquisiciones, fusiones, absorciones

Novo Nordisk, Omeros in Asset Purchase and License Pact for Omeros' Rare Blood and Kidney Disorder Drug

Comparación entre iguales

Cambio de precio

Omeros Corp previsión

Precio Objetivo

By TipRanks

71.63% repunte

Estimación a 12 Meses

Media 13.13 USD  71.63%

Máximo 20 USD

Mínimo 6.269 USD

De acuerdo con 3 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Omeros Corp Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

3 ratings

2

Comprar

1

Mantener

0

Vender

Puntuación técnica

By Trading Central

6.265 / 7.49Soporte y Resistencia

Corto Plazo

Very Strong Bearish Evidence

Medio plazo

Bearish Evidence

Largo Plazo

Weak Bullish Evidence

Sentimiento

By Acuity

29 / 371 Clasificación en Sanidad

Noticias sobre sentimiento de mercado

Coyuntura alcista notoria

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por debajo de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Omeros Corp

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19. It also develops OMS1029 that is in phase I clinical trials for long-acting second-generation antibody targeting lectin pathway disorders; OMS906 that has completed phase II clinical trials for Paroxysmal nocturnal hemoglobinuria, complement 3 glomerulopathy, and other alternative pathway disorders; and OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders. In addition, the company's products under preclinical development comprise MASP-2, a pro-inflammatory protein target for the treatment of lectin pathway disorders; MASP-3 small-molecule inhibitors for alternative pathway disorders; and Adoptive T-Cell and Chimeric Antigen Receptor (CAR) T-Cell Therapies and Immunomodulators/Immunotoxins/Cancer Vaccines for the treatment of various cancers. Omeros Corporation was incorporated in 1994 and is headquartered in Seattle, Washington.
help-icon Live chat